TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris

Withdrawn before enrolling · Phase 2

Conditions studied: Acne Vulgaris

In brief

The purpose of this study is to determine the safety and effectiveness of TSN 2898 topical gel in the treatment of moderate to severe acne.

Key facts

Study ID

NCT02796066

Run by

Thesan Pharmaceuticals, Inc.

People needed

0

Starts

2016-06-01

Expected to finish

2017-02-01

Last updated by the study team

2017-04-26

Who can join

Age: 16 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy males or females, 16 to 55 years of age
• Must be diagnosed as having moderate or severe acne vulgaris
• ≥ 20 inflammatory lesions on the face
• ≥ 20 non-inflammatory lesions on the face
• ≤ 3 nodule/cyst acne lesions
• Medically healthy
• Females must be of non-childbearing potential

You may not qualify if…

• Systemic therapy with retinoids within six (6) months prior to study start
• Topical use of prescription retinoids within four (4) weeks prior to study start
• Oral antibiotics within four (4) weeks prior to study start
• Topical dapsone, sulfacetamide, benzoyl peroxide, α-hydroxy/glycolic acid and retinol/retinaldehyde-containing products, and topical antibiotics, anti-inflammatory medications and corticosteroids on the face within two (2) weeks prior to study start
• Facial procedures, including lasers, peels, and dermabrasion, within two (2) months prior to study start

Where it is running

• Thesan Site 4 — San Diego, California, United States
• Thesan Site 3 — Miami, Florida, United States
• Thesan Site 6 — High Point, North Carolina, United States
• Thesan Site 5 — Johnston, Rhode Island, United States
• Thesan Site 2 — Santo Domingo, Dominican Republic
• Thesan Site 1 — San Pedro Sula, Honduras

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.